外科理论与实践 ›› 2025, Vol. 30 ›› Issue (03): 214-222.doi: 10.16139/j.1007-9610.2025.03.06
收稿日期:
2025-05-05
出版日期:
2025-05-25
发布日期:
2025-09-01
通讯作者:
顾凯,E-mail: gukai@scdc.sh.cn基金资助:
WU Chunxiao, PANG Yi, CHEN Lei, SHI Yan, GU Kai()
Received:
2025-05-05
Online:
2025-05-25
Published:
2025-09-01
摘要:
目的:分析2002—2020年上海市胆道癌发病和死亡的流行特征及其变化趋势。方法:采用上海市疾病预防控制中心建立的人群基础肿瘤登记管理系统和全死因登记系统收集的2002—2020年上海市胆囊和肝外胆管等胆道器官恶性肿瘤的发病和死亡资料,按诊断或死亡年份、性别和年龄组等因素分层分析,计算数量、构成比、粗率、年龄别率、年龄标准化率(简称标化率)等指标。标化率应用Segi’s 1960年世界标准人口构成调整计算。应用Joinpoint分析软件对胆道癌不同分组的标化年度变化百分比趋势、年龄别率和新发病例的部分诊断特征分类构成比进行分析。结果:上海市胆道癌的年新发病例数从2002年的963例逐年增长到2020年的1 537例,标化发病率从3.91/10万变化至3.59/10万,年死亡人数从830人逐年增长到1 225人,标化死亡率从3.36/10万减少至2.69/10万。2020年,上海市胆道癌粗发病率为10.43/10万,男性为9.54/10万,女性为11.30/10万,标化发病率为3.59/10万,男性为3.54/10万,女性为3.61/10万,性别间的差异没有统计学意义(P=0.731);粗死亡率为8.31/10万,男性为7.60/10万,女性为9.00/10万。标化死亡率为2.69/10万,男性为2.69/10万,女性为2.66/10万,性别间的差异也没有统计学意义(P=0.874)。发病和死亡的年龄别数量和率值总体上随着年龄的增长而增多。分性别趋势分析显示,2002—2020年上海市男性胆道癌的标化发病率变化无统计学意义(P=0.179),标化死亡率变化也无统计学意义(P=0.738);女性胆道癌的标化发病率以年均1.58%的减速下降(P<0.001),标化死亡率在2002—2011年间的变化无统计学意义(P=0.774),在2011—2020年间则以年均3.72%的减速下降(P<0.001)。新发病例通过病理确诊的占比上升,影像学检查确诊的占比下降。胆囊占比最多,但已显著下降,肝外胆管占比则从25.75%上升至42.88%。诊断时未分期占比超过60%,Ⅰ~Ⅲ期占比总和仍低于Ⅳ期占比。结论:上海市胆道癌标化发病率和死亡率相对较高,且呈现出差异较大的流行特征。上海在胆道疾病诊疗方面的提升,可能对胆道癌发病特征带来影响,而对提高生存率和降低死亡率的影响相对滞后,反映出在上海胆道癌的筛查、诊断和生存率提高上仍有较大的空间。本研究为胆道癌的进一步研究和预防控制提供了依据。
中图分类号:
吴春晓, 庞怡, 陈蕾, 施燕, 顾凯. 2002—2020年上海市胆道癌发病和死亡情况分析:基于人群基础的研究[J]. 外科理论与实践, 2025, 30(03): 214-222.
WU Chunxiao, PANG Yi, CHEN Lei, SHI Yan, GU Kai. Incidence and mortality analysis of biliary tract cancer in Shanghai: population-based study from 2002 to 2020[J]. Journal of Surgery Concepts & Practice, 2025, 30(03): 214-222.
表1
2020年上海市胆道癌发病和死亡概况
Category | Gender | Rank | Number | Proportion /% | Crude rate /10-5 | ASRa) /10-5 | TASRb) /10-5 | Cumulative rate /% | |||
---|---|---|---|---|---|---|---|---|---|---|---|
35-64 years | 0-64 years | 0-74 years | 0-84 years | ||||||||
Incidence | Both | 13 | 1 537 | 1.81 | 10.43 | 3.59 | 3.40 | 0.12 | 0.44 | 0.86 | |
Male | 13 | 695 | 1.56 | 9.54 | 3.54 | 3.46 | 0.13 | 0.45 | 0.81 | ||
Female | 10 | 842 | 2.09 | 11.30 | 3.61 | 3.35 | 0.12 | 0.44 | 0.91 | ||
Mortality | Both | 8 | 1 225 | 3.17 | 8.31 | 2.69 | 2.21 | 0.08 | 0.30 | 0.69 | |
Male | 9 | 554 | 2.30 | 7.60 | 2.69 | 2.10 | 0.08 | 0.33 | 0.64 | ||
Female | 7 | 671 | 4.63 | 9.00 | 2.66 | 2.32 | 0.08 | 0.28 | 0.73 |
表2
2020年上海市胆道癌分性别的发病和死亡年龄别率情况
Category | Age group/ year | Age-specific rates /10-5 | Ratio | Z value | P value | |
---|---|---|---|---|---|---|
Male | Female | |||||
Incidence | 30- | 0.53 | 0.18 | 2.92 | 0.98 | 0.327 |
35- | 0.53 | 0.86 | 0.61 | 0.68 | 0.494 | |
40- | 1.82 | 1.54 | 1.18 | 0.32 | 0.752 | |
45- | 0.64 | 1.26 | 0.51 | 0.97 | 0.330 | |
50- | 3.12 | 3.39 | 0.92 | 0.25 | 0.806 | |
55- | 6.03 | 5.09 | 1.19 | 0.75 | 0.451 | |
60- | 12.44 | 11.11 | 1.12 | 0.78 | 0.433 | |
65- | 22.85 | 22.59 | 1.01 | 0.09 | 0.925 | |
70- | 41.77 | 41.59 | 1.00 | 0.04 | 0.972 | |
75- | 38.82 | 43.33 | 0.90 | 0.75 | 0.453 | |
80- | 32.55 | 50.92 | 0.64 | 3.00 | 0.003 | |
≥85 | 73.34 | 73.46 | 1.00 | 0.01 | 0.990 | |
Mortality | 30- | 0.35 | - | - | - | - |
35- | - | 0.52 | - | - | - | |
40- | 0.45 | 0.88 | 0.52 | 0.78 | 0.433 | |
45- | 0.21 | 1.47 | 0.15 | 2.11 | 0.035 | |
50- | 1.91 | 3.03 | 0.63 | 1.20 | 0.230 | |
55- | 4.21 | 2.97 | 1.42 | 1.23 | 0.217 | |
60- | 8.71 | 6.88 | 1.27 | 1.32 | 0.187 | |
65- | 16.96 | 13.31 | 1.27 | 1.59 | 0.111 | |
70- | 33.77 | 26.07 | 1.30 | 1.83 | 0.067 | |
75- | 29.93 | 40.83 | 0.73 | 1.96 | 0.050 | |
80- | 32.01 | 49.33 | 0.65 | 2.86 | 0.004 | |
≥85 | 74.81 | 74.31 | 1.01 | 0.05 | 0.957 |
表3
2002—2020年上海市胆道癌分性别的发病和死亡年龄别率变化趋势
Category | Gender | Age group/ year | 2002 Rates (1/105) | Joinpoint | 2020 rates (1/105) | Trend 1 | Trend 2 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Year | rates (1/105) | Years | APC | t value | P value | Years | APC | t value | P value | |||||||
Incidence | Male | 30- | 0.46 | - | - | 0.53 | 2002-2020 | 1.61 | 0.80 | 0.440 | ||||||
35- | 0.32 | - | - | 0.53 | 2002-2020 | -2.33 | -0.97 | 0.348 | ||||||||
40- | 1.19 | - | - | 1.82 | 2002-2020 | 0.73 | 0.45 | 0.662 | ||||||||
45- | 1.88 | - | - | 0.64 | 2002-2020 | 0.48 | 0.32 | 0.751 | ||||||||
50- | 3.52 | - | - | 3.12 | 2002-2020 | 1.60 | 1.60 | 0.128 | ||||||||
55- | 6.73 | 2013 | 8.38 | 6.03 | 2002-2013 | 3.55 | 2.91 | 0.012 | 2013-2020 | -2.91 | -1.49 | 0.159 | ||||
60- | 8.31 | - | - | 12.44 | 2002-2020 | 1.11 | 1.76 | 0.097 | ||||||||
65- | 18.61 | - | - | 22.85 | 2002-2020 | 1.56 | 2.15 | 0.046 | ||||||||
70- | 26.75 | - | - | 41.77 | 2002-2020 | 0.51 | 0.763 | 0.456 | ||||||||
75- | 47.31 | - | - | 38.82 | 2002-2020 | -1.00 | -2.02 | 0.059 | ||||||||
80- | 55.97 | - | - | 32.55 | 2002-2020 | -2.41 | -3.72 | 0.002 | ||||||||
≥85 | 67.19 | - | - | 73.34 | 2002-2020 | 0.47 | 0.55 | 0.587 | ||||||||
Female | 30- | 0.27 | - | - | 0.18 | 2002-2020 | -8.45 | -6.64 | <0.001 | |||||||
35- | 0.51 | - | - | 0.86 | 2002-2020 | -3.53 | -1.72 | 0.103 | ||||||||
40- | 0.97 | - | - | 1.54 | 2002-2020 | -0.82 | -0.46 | 0.652 | ||||||||
45- | 2.81 | - | - | 1.26 | 2002-2020 | -0.24 | -0.23 | 0.820 | ||||||||
50- | 5.42 | - | - | 3.39 | 2002-2020 | -1.56 | -2.09 | 0.052 | ||||||||
55- | 12.31 | - | - | 5.09 | 2002-2020 | -2.63 | -4.54 | <0.001 | ||||||||
60- | 17.03 | - | - | 11.11 | 2002-2020 | -1.76 | -2.93 | 0.009 | ||||||||
65- | 21.68 | - | - | 22.59 | 2002-2020 | -0.98 | -1.82 | 0.087 | ||||||||
70- | 46.13 | - | - | 41.59 | 2002-2020 | -1.49 | -2.94 | 0.009 | ||||||||
75- | 58.56 | - | - | 43.33 | 2002-2020 | -1.89 | -4.11 | 0.001 | ||||||||
80- | 70.72 | 2011 | 83.96 | 50.92 | 2002-2011 | 0.58 | 0.47 | 0.645 | 2011-2020 | -5.61 | -5.32 | <0.001 | ||||
≥85 | 63.54 | 2009 | 87.42 | 73.46 | 2002-2009 | 4.28 | 2.38 | 0.032 | 2009-2020 | -2.15 | -3.57 | 0.003 | ||||
Mortality | Male | 35- | 0.16 | - | - | 0.35 | 2002-2020 | 0.53 | 0.15 | 0.885 | ||||||
40- | 0.53 | - | - | 0.45 | 2002-2020 | 0.55 | 0.26 | 0.801 | ||||||||
45- | 0.94 | - | - | 0.21 | 2002-2020 | -1.01 | -0.59 | 0.561 | ||||||||
50- | 2.35 | - | - | 1.91 | 2002-2020 | 1.92 | 1.25 | 0.228 | ||||||||
55- | 4.89 | - | - | 4.21 | 2002-2020 | 1.16 | 1.03 | 0.318 | ||||||||
60- | 7.59 | - | - | 8.71 | 2002-2020 | 1.02 | 1.25 | 0.230 | ||||||||
65- | 14.12 | - | - | 16.96 | 2002-2020 | 1.11 | 1.97 | 0.066 | ||||||||
70- | 23.46 | - | - | 33.77 | 2002-2020 | 0.21 | 0.26 | 0.797 | ||||||||
75- | 36.10 | - | - | 29.93 | 2002-2020 | -0.54 | -1.02 | 0.323 | ||||||||
80- | 49.61 | - | - | 32.01 | 2002-2020 | -2.07 | -4.06 | 0.001 | ||||||||
≥85 | 89.58 | - | - | 74.81 | 2002-2020 | -0.12 | -0.18 | 0.859 | ||||||||
Female | 35- | 0.34 | - | - | 0.52 | 2002-2020 | -1.83 | -0.82 | 0.431 | |||||||
40- | 0.55 | - | - | 0.88 | 2002-2020 | -0.45 | -0.26 | 0.797 | ||||||||
45- | 2.25 | - | - | 1.47 | 2002-2020 | 0.57 | 0.48 | 0.639 | ||||||||
50- | 5.21 | - | - | 3.03 | 2002-2020 | -2.49 | -2.42 | 0.027 | ||||||||
55- | 8.52 | - | - | 2.97 | 2002-2020 | -3.22 | -5.91 | <0.001 | ||||||||
60- | 13.48 | - | - | 6.88 | 2002-2020 | -2.08 | -2.59 | 0.019 | ||||||||
65- | 24.00 | - | - | 13.31 | 2002-2020 | -1.98 | -4.69 | <0.001 | ||||||||
70- | 39.49 | - | - | 26.07 | 2002-2020 | -1.95 | -4.27 | 0.001 | ||||||||
75- | 48.96 | 2010 | 64.28 | 40.83 | 2002-2010 | 1.73 | 1.50 | 0.156 | 2010-2020 | -4.13 | -4.99 | <0.001 | ||||
80- | 62.40 | 2011 | 85.40 | 49.33 | 2002-2011 | 2.02 | 1.30 | 0.215 | 2011-2020 | -5.79 | -4.49 | 0.001 | ||||
≥85 | 70.30 | 2009 | 102.34 | 74.31 | 2002-2009 | 5.56 | 3.12 | 0.007 | 2009-2020 | -2.73 | -4.61 | <0.001 |
表4
2002—2020年上海市胆道癌诊断特征分类构成比变化趋势
Category | 2002 | Joinpoint | 2020 | Trend 1 | Trend 2 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentage/% | Year | Percentage/% | Percentage/% | Years | APC | t value | P value | Years | APC | t value | P value | |||
Diagnostic basis | ||||||||||||||
Morphological verification | 39.36 | - | - | 44.50 | 2002-2020 | 1.73 | 7.05 | <0.001 | ||||||
Imaging verification | 40.50 | - | - | 22.64 | 2002-2020 | -3.75 | -12.54 | <0.001 | ||||||
Others | 20.15 | - | - | 32.86 | 2002-2020 | 1.56 | 4.65 | <0.001 | ||||||
Anatomic site | - | - | ||||||||||||
Gallbladder | 61.47 | - | - | 48.93 | 2002-2020 | -1.09 | -9.97 | <0.001 | ||||||
Extrahepatic bile ducts | 25.75 | 2011 | 37.06 | 42.88 | 2002-2011 | 3.65 | 8.74 | <0.001 | 2011-2020 | 1.80 | 4.36 | 0.001 | ||
Others | 12.77 | - | - | 8.20 | 2002-2020 | -3.00 | -7.93 | <0.001 | ||||||
Histological type | - | - | ||||||||||||
Cholangiocarcinom | 3.74 | 2009 | 11.71 | 13.01 | 2002-2009 | 17.97 | 8.67 | <0.001 | 2009-2020 | 0.53 | 0.55 | 0.591 | ||
Adenocarcinoma, others | 27.21 | - | - | 25.44 | 2002-2020 | -0.26 | -0.83 | 0.418 | ||||||
Others and unspecified | 69.06 | - | - | 61.55 | 2002-2020 | -0.63 | -5.29 | <0.001 | ||||||
Stage | - | - | ||||||||||||
Ⅰ | 4.15 | - | - | 2.67 | 2002-2020 | -0.47 | -0.66 | 0.521 | ||||||
Ⅱ | 6.75 | - | - | 5.79 | 2002-2020 | -0.31 | -0.55 | 0.593 | ||||||
Ⅲ | 7.89 | - | - | 6.05 | 2002-2020 | -0.06 | -0.13 | 0.900 | ||||||
Ⅳ | 18.80 | - | - | 19.71 | 2002-2020 | 0.42 | 1.29 | 0.215 | ||||||
Unknown | 62.41 | - | - | 65.78 | 2002-2020 | -0.08 | -0.49 | 0.629 |
[1] | WHO Classification of Tumours Editorial Board. Digestive system tumours[M]// World Health Organization classification of tumours, 5th ed. Geneva: WHO Press, 2024. |
[2] | BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. |
[3] | 顾凯, 庞怡, 吴春晓, 等. 2017年上海市恶性肿瘤发病和死亡情况与2002—2017年的变化趋势分析[J]. 肿瘤, 2023, 43(4):241-256. |
GU K, PANG Y, WU C X, et al. Analysis of the current status of cancer incidence and mortality in Shanghai, 2017 and trends of 2002-2017[J]. Tumor, 2023, 43(4):241-256. | |
[4] | 国家癌症中心. 中国肿瘤登记工作指导手册(2016)[M]. 北京: 人民卫生出版社,2016:59-75. |
National Cancer Center. Chinese guideline for cancer re-gistration(2016)[M]. Beijing: People's Medical Publishing House,2016:59-75. | |
[5] | PARKIN D M, CHEN V W, FERLAY J, et al. Comparability and quality control in cancer registration. IARC Technical Report No.19[M]. Lyon: IARC Press,1994. |
[6] | 上海市疾病预防控制中心. 上海市恶性肿瘤发病率、死亡率和生存率(2001—2012)[M]. 上海: 上海科学普及出版社,2017:1-6. |
Shanghai Municipal Center for Disease Control & Prevention. Cancer incidence, mortality and survival rates in Shanghai(2001—2012)[M]. Shanghai: Shanghai General Science Press,2017:1-6. | |
[7] | 卢伟, 郑莹. 肿瘤命名与编码[M]. 上海: 第二军医大学出版社, 2011. |
LU W, ZHENG Y. Tumor nomenclature and coding[M]. Shanghai: Second Military Medical University Press, 2011. | |
[8] | SEGI M. Cancer mortality for selected sites in 24 countries (1950—1957)[M]. Sendai: Tohoku University School of Medicine,1960. |
[9] | Statistical Research and Applications Branch, National Cancer Institute. Joinpoint Regression Program, Version 4.8.0.1[CP]. Bethesda,Maryland: National Cancer Institute, 2020. |
[10] |
KIM H J, FAY M P, FEUER E J, et al. Permutation tests for joinpoint regression with applications to cancer rates[J]. Stat Med, 2000, 19(3):335-351.
doi: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z pmid: 10649300 |
[11] | ESTÈVE J, BENHAMOU E, RAYMOND L. Statistical methods in cancer research. Volume Ⅳ. Descriptive epidemiology[J]. IARC Sci Publ, 1994,(128):1-302. |
[12] | HAN B, ZHENG R, ZENG H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53. |
[13] | 国家癌症中心. 2022中国肿瘤登记年报[M]. 北京: 人民卫生出版社,2025:148-151. |
National Cancer Center. 2022 Chinese cancer registry annual report[M]. Beijing: People′s Medical Publishing House,2025:148-151. | |
[14] | P BRAY F, COLOMBET M, AITKEN JF, et al. Cancer incidence in five continents Vol. Ⅻ. IARC Scientific Publications No.169[M]. Lyon: International Agency for Research on Cancer, 2024. |
[15] | 杨晓静, 王家冉, 靳婷, 等. 2000—2021年浙江省肿瘤登记地区胆囊癌的流行现状与趋势分析[J]. 中国普外基础与临床杂志, 2025, 32(6):714-721. |
YANG X J, WANG J R, JIN T, et al. Analysis of the prevalence status and trend of gallbladder cancer in Zhejiang Province from 2000 to 2021[J]. Chin J Bases Clin Gen Surg, 2025, 32(6):714-721. | |
[16] | 沈欢, 孙中明, 缪丹丹, 等. 2009—2019年江苏省肿瘤登记地区胆囊癌发病趋势及年龄变化分析[J]. 中国肿瘤外科杂志, 2024, 16(3):215-220. |
SHEN H, SUN Z M, MIAO D D, et al. Analysis on the trends of gallbladder cancer incidence and age change in cancer registration regions of Jiangsu Province,2009 to 2019[J]. Chin J Surg Oncol, 2024, 16(3):215-220. | |
[17] | LEWIS S J, HEATON K W, OAKEY R E, et al. Lower serum oestrogen concentrations associated with faster intestinal transit[J]. Br J Cancer, 1997, 76(3):395-400. |
[18] | 吴春晓, 鲍萍萍, 黄哲宙, 等. 上海市消化系统常见恶性肿瘤发病现况和时间趋势分析[J]. 胃肠病学, 2012, 17(9):513-520. |
WU C X, BAO P P, HUANG Z Z, et al. Current prevalence of common digestive system cancer in Shanghai and analysis of its trends[J]. Chin J Gastroenterol, 2012, 17(9):513-520. | |
[19] | CHAN T F, WU C H, CHIU H F, et al. Parity and risk of death from gallbladder cancer among a cohort of premenopausal parous women in Taiwan[J]. Int J Environ Res Public Health, 2015, 12(2):1864-1873. |
[20] |
EKBOM A, HSIEH C C, YUEN J, et al. Risk of extrahepatic bileduct cancer after cholecystectomy[J]. Lancet, 1993, 342(8882):1262-1265.
pmid: 7901583 |
[21] | HSING A W, GAO Y T, HAN T Q, et al. Gallstones and the risk of biliary tract cancer: a population-based study in China[J]. Br J Cancer, 2007, 97(11):1577-1582. |
[22] |
NOGUEIRA L, FREEDMAN N D, ENGELS E A, et al. Gallstones, cholecystectomy, and risk of digestive system cancers[J]. Am J Epidemiol, 2014, 179(6):731-739.
doi: 10.1093/aje/kwt322 pmid: 24470530 |
[23] | 吴春晓, 顾凯, 庞怡, 等. 2002—2013年上海市恶性肿瘤生存分析[J]. 肿瘤, 2023, 43(4):257-265. |
WU C X, GU K, PANG Y, et al. Survival analysis of cancer cases diagnosed during 2002—2013 in Shanghai: a population-based study[J]. Tumor, 2023, 43(4):257-265. | |
[24] | HENLEY S J, WEIR H K, JIM M A, et al. Gallbladder cancer incidence and mortality, United States 1999-2011[J]. Cancer Epidemiol Biomarkers Prev, 2015, 24(9):1319-1326. |
[25] | 郑杨, 王春芳, 吴春晓, 等. 《“健康上海2030”规划纲要》三项主要指标解读[J]. 上海预防医学, 2018, 30(1):11-14. |
ZHENG Y, WANG C F, WU C X, et al. Interpretation of three main indicators of the “2030 Plan for Healthy Shanghai”[J]. Shanghai J Prev Med, 2018, 30(1):11-14. |
[1] | 李金彩. 跨界对话中的语言哲学新图景:理论互鉴与方法革新——上海交通大学首届“语言哲学前沿论坛”综述及学科发展前瞻[J]. 当代外语研究, 2025, 25(3): 198-204. |
[2] | 赖柏翰, 魏伯轩, 金佳敏, 等. 中国先天性巨大黑痣的流行病学以及危险因素调查研究[J]. 组织工程与重建外科杂志, 2025, 21(3): 250-. |
[3] | 康敏, 施静. 1990—2019年中国烟草相关哮喘疾病负担的年龄-时期-队列分析及预测[J]. 内科理论与实践, 2025, 20(03): 242-247. |
[4] | 周晓蝶, 戚荣鑫, 王璇, 余波, 王建军, 石群立, 饶秋, 鲍炜. 尿路上皮癌PD-L1、AR及P53表达及其与临床预后相关性[J]. 诊断学理论与实践, 2025, 24(03): 286-292. |
[5] | 杜雅洁, 王铭飞, 林茂松. 结直肠癌中KIAA1429通过上调PD-L1及下调CD8+ T细胞组织浸润而抑制抗肿瘤免疫的研究[J]. 诊断学理论与实践, 2025, 24(03): 301-311. |
[6] | 吴琪, 范伯男, 李岩. 2022全球癌症统计报告分析解读:中国与世界癌症疾病负担与流行趋势[J]. 诊断学理论与实践, 2025, 24(02): 135-145. |
[7] | 王军, 胡刚峰, 高伟陈, 王路兵. 海兰地嗪通过AMPK/mTOR信号通路诱导肝细胞癌自噬性死亡[J]. 外科理论与实践, 2025, 30(02): 138-145. |
[8] | 张计委, 吴小琼, 崔金煌, 俞春明, 黎衍云. 中老年人群糖代谢状态与全因死亡及心脑血管疾病死亡风险的关联研究[J]. 内科理论与实践, 2025, 20(02): 120-125. |
[9] | 沈世仲, 隋亮, 陈康, 史晓, 施丹. “肾藏精,主骨”理论与男性骨质疏松症[J]. 内科理论与实践, 2025, 20(01): 94-100. |
[10] | 徐荆庶, 施建华, 顾海雁, 陈蕾, 钱孝琳, 陆璐, 钮登. 1992—2021年上海市徐汇区户籍居民胰腺癌死亡率趋势分析[J]. 外科理论与实践, 2025, 30(01): 34-40. |
[11] | 丁帅, 张广泉, 高坤, 等. 利拉鲁肽通过抑制铁死亡实现对脊髓损伤大鼠的神经保护作用[J]. 组织工程与重建外科杂志, 2024, 20(4): 422-. |
[12] | 郑鸿鲲, 单圣周, 季向阳, 等.
病理性瘢痕的多组学方法研究进展
[J]. 组织工程与重建外科杂志, 2024, 20(3): 362-. |
[13] | 李东东, 王斌. 先天性黑素细胞痣的发病机制及诊疗策略[J]. 组织工程与重建外科杂志, 2024, 20(2): 254-. |
[14] | 陈微微, 孙良丹. 中国人群银屑病遗传流行病学研究进展[J]. 诊断学理论与实践, 2024, 23(06): 561-567. |
[15] | 范凯健, 刘金渝, 赵福涛. 重视干燥综合征的早期诊断[J]. 内科理论与实践, 2024, 19(06): 417-421. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||